Resalis Therapeutics, a Torino, Italy-based company focused on finding treatments for metabolic diseases, raised €10M in Seed funding.
The round was led by Claris Ventures, with participation from Italian Angels for Growth and Club degli Investitori. Pietro Puglisi, Managing Partner at Claris Ventures, joined Resalis’ Board of Directors.
The company intends to use the funds to support the finalization of IND-enabling studies for its lead program, RES-010.
Led by CEO Alessandro Toniolo, Resalis Therapeutics targets a master regulator of multiple pathways underlying obesity and fatty liver disease. The company is applying the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. The company is now focused on IND-enabling studies to support a first-in-human clinical trial in early 2024.
FinSMEs
22/02/2023